Based on the inheritance, the research group summarized the transmissive pathogenesis of depression in three typical stages, formulating the stepward treatment units which included Chinese medicine, acupuncture and TCM characterized psychotherapy, and formed a sequential treatment plan that balanced the principle of strengthening healthy Qi to eliminate pathogens, active and passive treatment, physical therapy and psychotherapy. Based on the retrospective analyses, ten typical clinical syndromes have been formed, constituting the pattern differentiation of "Three Phases, Five internal organs and Ten syndromes" for depression, which sysmatically showed the TCM syndrome differentiation. This work promoted the experiences and methods of treating depression by Chinese medicine.

On the basis of relevant literature, according to the clinical experience of Tuina specialists, a preliminary plan of Tuina for nonspecific low back pain has been formed. An expert consensus meeting was used to form a non-specific low back pain assessment program and 3 modern Gongting Lijinshu (Tuina massage) for the treatment of nonspecific low back pain. The treatment has showed to be clinically repeatable and suitable for the RCT study.

Objective To investigate the constitutional types of Chinese medicine of primary bile reflux gastritis among different seasons. Methods Data of gastroscopy center during August 2015 to July 2016 were analyzed. A total of 603 patients were diagnosed as primary bile reflux gastritis. After gastroscopy, the standardized constitution in Chinese medicine questionnaire was used to evaluation the scores of all kinds of constitutional types. The Constitutional types of Chinese medicine of primary bile reflux gastritis among different seasons were analyzed. Results Among all seasons, the positive detection rate showed significant difference (χ2=13.041, P=0.005), and summer group showed the highest among the four seasons (23.38% vs. 17.63%,χ2=12.414, P<0.001). Among all seasons, constitutional types of Chinese medicine of primary bile reflux gastritis had significant difference (χ2=37.441, P<0.001). Damp-heated type had significant difference among seasons (χ2=8.472, P=0.037), especially during the summer (χ2=5.847, P=0.016). Conclusions The summer may have more primary bile reflux gastritis chance to be diagnosed as primary bile reflux gastritis. Yang-deficiency type, Gentleness type, Qi-deficiency type and damp-heat type were more common in primary bile reflux gastritis patients.

Objective To investigate the effect of Shenqi-Tongmai decoction in Stable Angina pectoris Patients with Qi-deficiency-blood-stasis syndrome and the influence on serum associated adhesion factors. Methods A total of 110 patients with stable angina pectoris treated in the department of cardiology of traditional Chinese medicine hospital of Xinle city from Feb. 2015 to Feb. 2017 were divided into 2 groups according to the number random table method, with 55 in each group. All the patients were given the standardized treatment with western medicine, and the treatment group were aditionally treated with the Shenqi-Tongmai decoction. All the patients were treated for a course of 4 weeks. The TCM syndrome score, Seattle angina questionnaire (SAQ) score, electrocardiographic examination index and serum soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1) level of the two groups before and after treatment were compared, and the clinical curative effect of the two groups was compared. Results The TCM syndrome score (7.1 ± 2.2 vs. 11.4 ± 3.0, t=8.590), serum sICAM-1 (227.69 ± 42.81 ng/ml vs. 275.33 ± 48.62 ng/ml, t=5.454) level, serum sVCAM-1 (272.04 ± 39.87 ng/ml vs. 296.58 ± 42.60 ng/ml, t=3.127) level and lead ecg ST segment down number (2.7 ± 0.6 vs. 3.2 ± 0.6, t=4.067), T wave of low lead numbers (1.7 ± 0.3 vs. 2.1 ± 0.3, t=6.807), numbers of T wave inversion lead (1.7 ± 0.3 vs. 2.1 ± 0.2, t=9.908) of the treatment group were significantly lower than those of the control group (P<0.01). The SAQ scores (76.8 ± 10.5 vs. 67.4 ± 10.1, t=4.805) was higher than that of the control group (P<0.01). The curative effect of angina pectoris and electrocardiogram of the treatment group were 91.0% (50/55) and 92.7%(51/55), and the control group were 76.4% (42/55) and 78.2% (43/55). The difference was statistically significant between the two groups (χ2=4.251, 4.681, P<0.05). Conclusions Traditional Chinese medicine Shenqi-Tongmai decoction can effectively improve the SAQ scores and TCM syndrome score and electrocardiogram examination index, improve the clinical curative effect in the treatment of Stable Angina pectoris based on the western medicine (Qi-deficiency-blood-stasis syndrome) and its mechanism may be related to improving of the serum levels of sICAM 1, sVCAM 1.

Objective To investigate the clinical efficacy and mechanism of Huoxue-Qingjie decoction for acute pancreatitis (AP). Methods According to the random table method, 89 patients with AP from April 2015 to March 2017 were divided into control group (n=44) and observation group (n=45). Two groups of patients were treated with conventional treatment, while the observation group was treated with Huoxue-Qingjie decoction on the basis of routine treatment for 7 days. The clinical total effective rate and improvement of clinical symptoms of two groups of patients were counted, at the same time the serum inflammation and oxidative stress indicators of patients were detected respectively before and after treatment. In addition, the incidence of adverse reactions of two groups of patients was analyzed.. Results The total clinical efficiency of the patients in the observation group was 86.7% (39/45), while the control group was 68.2% (30/44). The difference of two groups was statistically significant (χ2=4.363, P=0.037). The imaging returning to normal time (6.3 ± 1.2 d vs. 9.1 ± 1.1 d, t=-12.161), anal exhausted time (35.7 ± 6.8 h vs. 45.6 ± 7.2 h, t=-6.659), abdominal distension relief time (3.0 ± 0.8 d vs. 3.7 ± 0.9 d, t=-4.154) and bowel sounds recovery time (32.5 ± 5.5 h vs. 39.9 ± 6.1 h, t=-5.998) of the observation group were significantly lower than those of the control group (P<0.01). After treatment, the levels of TNF-α (101.21 ± 17.65 ng/L vs. 132.07 ± 20.32 ng/L, t=-7.654), IL-1β (20.33 ± 6.21 pg/ml vs. 29.03 ± 7.03 pg/ml, t=-6.191), IL-6 (30.07 ± 7.32 ng/L vs. 51.71 ± 7.05 ng/L, t=-14.200), IL-8 (80.23 ± 15.22 ng/L vs. 100.56 ± 16.37 ng/L, t=-6.069), HMGB1 (1.35 ± 0.43 μg/L vs. 2.63 ± 0.57 μg/L, t=-11.977) and MDA (3.02 ± 0.64 nmol/L vs. 4.02 ± 0.83 nmol/L, t=-6.374) of the treatment group were significantly lower than those of the control group (P<0.01), while the levels of SOD (119.63 ± 15.69 U/ml vs. 98.54 ± 10.73 U/ml, t=7.836) and CAT (238.87 ± 42.67 U/ml vs. 196.36 ± 39.65 U/ml, t=4.866) were significantly higher than those of control group (P<0.01). No serious adverse reactions occurred during the treatment of the two groups. Conclusions The clinical effect of Huoxue-Qingjie decoction on AP is significant, and the clinical symptoms can be improved by anti-inflammatory and anti-oxidative effect. The safety is high, and it is worth promoting the application in clinic.

Objective To research of Huangong decoction combined with routine treatment of western medicine for the postpartum hemorrhage and fundus reduced height of the postpartum hemorrhage (PPH). Methods A total of 242 patients with postpartum hemorrhage were enrolled and divided into two group by random number table: the treatment group (121 patients) and the control group (121 patients). Patients in the control group were treated with the western medicine routine treatment, while the treatment group were treated with Huangong decoction plus routine treatment. Both groups were treated for 3 days with a follow-up of 42 d. The postpartum haemorrhage amount, fundus height reduction were compared. The clinical effect rate was evaluated with postpartum haemorrhage amount, palace at the uterine bottom of the height reduction. Results The total clinical effectiveness rate of the treatment group was 97.5% (118/121), and the control group was 90.1%(109/121). The difference of two groups was statistically significant (χ2=4.478, P=0.034). After production, the uterine bottom height reduction at the first day (9.3 ± 1.4 mm vs. 8.0 ± 1.3 mm, t=7.501), the second day (10.2 ± 1.2 mm vs. 9.1 ± 1.1 mm, t=7.447) and the third day (12.2 ± 1.5 mm vs. 10.1±1.4 mm, t=11.283) in the treatment group were significantly greater than the control group (P<0.01). The postpartum hemorrhage at the first day (732.1 ± 84.3 ml vs. 766.4 ± 90.0 ml, t=-3.066), the second day (480.1 ± 62.0 ml vs. 590.0 ± 74.3 ml, t=-12.513) and the third day (240.4 ± 36.3 ml vs. 340.3 ± 52.0 ml, t=-17.351) in the treatment group were significantly less than the control group (P<0.01). After postpartumt, the uterine volume (632.1 ± 101.2 mm3 vs. 701.4 ± 135.7 mm3, t=-5.095) at third day and (142.3 ± 16.5 mm3 vs. 160.6 ± 19.7 mm3, t=-7847) at the follow-up, in the treatment group were significantly less than the control group (P<0.01). Conclusions The Huangong decoction combined with routine treatment of western medicine can improve the clinical symptoms in patients with PPH, and contribute to the recovery of disease.

Objective To observe the clinical effect of the Bushen-Qiangjin capsule and calcium D in the treatment of aromatase inhibitors-associated bone loss (AIBL) in breast cancer patients. Methods A total of 65 patients were randomized into a treatment group and a control group, 32 in the control group taking calcium D, and 33 in the treatment group taking calcium D and Bushen-Qiangjin capsule. After a 3-month treatment, the bone mineral density T (BMD), bone-specific alkaline phosphatase (BALP), bone gla protein (BGP) and tartrate resistant acid phosphatase (TrACP) of two groups were evaluated. Results The BMD increased significantly after treatment in both groups (P<0.05), and the therapeutic efficacy of the treatment group was better than of the control group (P<0.05). After treatment, the level of BALP (308.76 ± 10.99 U/L vs. 280.00 ± 7.44 U/L, t=8.170) and the BGP (42.21 ± 3.04 ng/ml vs. 34.38 ± 2.06 ng/ml, t=6.818) of the treatment group were significantly higher than those of the control group (P<0.01). The level of TrACP decreased significantly after treatment in both groups (P<0.05), and the TrACP (60.12 ± 4.58 U/L vs. 67.25±4.06 U/L, t=1.653) of treatment group was significantly lower than that of the control group (P<0.05). Conclusions The Bushen-Qiangjin capsule can produce a content efficacy in treating AIBL in breast cancer patients, improving the BMD and bone metabolism.

Objective To evaluate the curative effect of the Duhuo-Jisheng decoction in treating knee osteoarthritis (KOA) with the deficiency of liver and kidney. Methods Using the random number table method, a total of 80 KOA patients were randomly divided into 2 group, 40 in each group. The treatment group were treated with Duhuo-Jisheng decoction, and the control group with glucosamine sulfate orally. The 2 groups were treated with 30 day. The blood sedimentation (ESR) of before and after treatment was detected. The level of C-reactive protein (CRP) was detected by latex enhanced immunization. The degree of knee joint pain was evaluated by VAS scale. The severity of the symptoms was evaluated by the visual scale of Osteoarthritis Index (Western Ontario Mac Master University Osteoarthritis index, WOMAC index). The changes of TCM symptoms were observed and the clinical effective rate was evaluated. Results The total effective rate of the treatment group was 95% (38/40), while the control group was 77.5% (31/40). The difference between the 2 groups was statistically significant (χ2=10.213, P=0.003). After treatment, the ESR (15.41 ± 4.23 mm/h vs. 17.6 ± 7.27 mm/h, t=-4.426), CRP (4.73 ± 1.28 mg/L vs. 6.12 ± 2.38 mg/L, t=-14.735) level in the treatemnt group were significantly lower than those in the control group (P<0.01). The VAS scores (2.5 ± 0.62 vs. 4.9 ± 0.8, t=-15.026), WOMAC index(12.1 ± 4.7 vs. 16.7 ± 6.7, t=-11.177) and TCM symptom score (6.5 ± 0.4 vs. 7.5 ± 0.4, t=-3.482) in the treatment group were significantly lower than those in the control group (P<0.01). Conclusions The Duhuo-Jisheng decoction is effective improve the symptom and quality of life of liver-kidney deficiency of KOA.

Objective To observe the curative effect of traditional Chinese medicine fumigation combined with manipulation massage on children with muscular torticollis. Methods Sixty-two children with torticollis were enrolled in our hospital from January 2015 to November 2016. They were randomly divided into control group (n=31) and observation group (n=31). The control group was treated with different methods of massage, and the observation group was treated with traditional Chinese medicine based on the control group. The treatment last for 3 months. The clinical effect, cervical rotation score, muscle contracture score, head tilt score, head malformations were observed. The Doppler ultrasound was used for the mass thickness and elastic coefficient of sternocleidomastoid. Results After 3 months treatment, the total effective rate was 93.5% (29/31) in the observation group, 77.4% (24/31) in the control group, and the difference between two groups were statistically significant (χ2=6.902, P=0.039). The cervical rotation score (2.8 ± 0.2 vs. 1.7 ± 0.3, Z=7.698), the muscle contracture score (2.7 ± 0.4 vs. 1.6 ± 0.4, Z=6.949), the head tilt score (2.8 ± 0.2 vs. 1.6 ± 0.4, Z=8.021), the head malformations score (2.4 ± 0.5 vs. 2.0 ± 0.3, Z=5.949) in the observation group were significantly higher than those in the control group (P<0.05). The mass thickness (6.23 ± 1.18 mm vs. 9.02 ± 1.19 mm, Z=10.075) in the observation group was significantly lower than that in the control group (P<0.01). The time of cure (30.4 ± 14.0 d vs. 59.2 ± 12.2 d, Z=10.218) and the time of improvement (34.6 ± 11.3 d vs. 55.2 ± 15.5 d, Z=11.249) in the observation group were significantly lower than those in the control group (P<0.05). Conclusions The Chinese medicine fumigation combined with manipulation could treat the children with muscular torticollis.

Objective To analyze the treatment and medication rules of formulae containing prepared rehmannia root in Pharmaceutical Standard of Ministry of Public Health of the People's Republic of China-Traditional Chinese Patent Medicine (referred to as Traditional Chinese Patent Medicine). Methods Through Traditional Chinese Medicine Inheritance Support Platform (V2.5), prescriptions containing prepared rehmannia root in traditional Chinese patent medicine were selected and collected to build the database. Frequency counts,association rules and other data mining methods were used to analyze the frequency of indication syndromes and medicine combination of prescription containing prepared rehmannia root, and the compatibility rule of high frequency drug pairs and the rescription rule of core syndromes were analyzed. Results There were a total of 467 prescriptions containing pepared rehmannia root, involving 28 combinations of commonly used Chinese herbals (support degree 30%). The compatibility source of high-frequency drug pairs of prepared rehmannia root and Angelicae Sinensis, prepared rehmannia root and Astragalus embranaceus were both of Shiquan-Dabu decoction in Taiping Huimin Heji Ju Fang (support degree 40%). There were a total of 81 indication syndromes, and among them, there were 16 kinds of high-frequency indication syndromes (the frequency greater than or equal to 10). The core drug combination of high-frequency indication syndromes of "deficiency of both qi and blood" (137 times) and "deficiency of kidney yang" (63 times) were the subtract of Shiquan-Dabu decoction and Yougui pill in Jingyue Quanshu respectively. Conclusions Prepared rehmannia root is mainly compatible with herbs of nourishing blood, supplementing qi and invigorating yang in the traditional Chinese patent medicine containing prepared rehmannia root. The traditional Chinese patent medicine containing prepared rehmannia root were based mainly on classical prescriptions. This study can provide reference for clinical application and new drug development of pepared rehmannia root.